Fabry-Anderson disease: Current state of knowledge;La enfermedad de Fabry-Anderson: Estado actual del conocimiento

Revista de Investigacion Clinica

Volumn 63, Issue 3, 2011, Pages 314-321

  Vega Vega, Olynka ^a   Pérez Gutiérrez, Angélica ^a   Correa Rotter, Ricardo ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

galactosidase; Fabry Anderson disease; Glycosphingolipids; Lysosomal storage disease; Physiopathology

Indexed keywords

ENZYME REPLACEMENT; FABRY DISEASE; GENETICS; METABOLIC DISORDER; MOLECULAR BIOLOGY; REVIEW;

ALPHA-GALACTOSIDASE; ALPHA-N-ACETYLGALACTOSAMINIDASE; CHROMOSOMES, HUMAN, X; COHORT STUDIES; ENDOTHELIUM, VASCULAR; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; HUMANS; KIDNEY; LYSOSOMES; MALE; MYOCARDIUM; ORGAN SPECIFICITY; PHENOTYPE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80052132733     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Fabry J. Ein Beitrag Zur Kenntnis der Purpura haemorrhagica nodularis. Arch Dermatol Syphilis 1898; 43: 187-200.
2. Anderson WA. A case of angioqueratoma. Br J Dermatol 1898; 10: 113-7.
3. Pompen AWM, Ruiter M, Wyers HJG. Angiokeratoma corporis diffusum (universale) Fabry, as a sign of an unknown internal disease: two autopsy reports. Act Med Scand 1947; 1128: 234-55.
4. Sweeley CC. Fabry's disease: classification as sphingolipidosis and partial characterization of a novel glycolipid. J Biol Chem 1963; 238: 3148-50.
5. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967; 296: 1163-7.
6. Kornreich R, Bishop DF, Desnick RJ. The gene encoding alpha-galactosidase A and gene rearrangements causing Fabry disease. Trans Assoc Am Physicians 1989; 102: 30-43.
7. Meikle PJ, Hopwood JJ, Clague AE, Cary WF. Prevalence of lysosomal storage disordes. JAMA 1999; 281: 249-54.
8. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 2006; 79: 31-40. (Pubitemid 43927374)
9. Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002; 105: 1407-11. (Pubitemid 34263268)
10. Rolfs A, Böttcher T, Zschiesche M, et al. Prevalence of Fabry disease in patients with cryptogenic sroke: a prospective study. Lancet 2005; 366: 1794-6. (Pubitemid 41642643)
11. Spada M, Pagliardini S. Screening for Fabry disease in end stage nephropaties. J Inherit Metab Dis 2002; 25(Suppl.): S113.
12. Merta M, Reiterova J, Ledvinova J, et al. A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. Nephrol Dial Transplant 2007; 22: 179-86. (Pubitemid 46050343)
13. Nakao S, Kodoma C, Takenaka T, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a renal variant phenotype. Kidney Int 2003; 64: 801-7. (Pubitemid 37013815)
14. Linthorst GE, Hollark CE, Korevaar JC. A critical appraisal of screening ofr Fabry disease. Nephrol Dial Transplant 2003; 18: 1581-4.
15. Bekri S, Enica A, Ghafari T, et al. Fabry disease in patients with end stage renal failure: the potential benefits of screening. Nephrol Clin Pract 2005; 101: 33-5.
16. Desnick RJ, Ioannou YA, Eng CM. Alfa-galactosidase a deficiency: Fabry disease. New York: McGraw-Hill; 2001, p. 3733-74.
17. Bishop DF, Calhoun DH, Bernstein HS, Hantzopoulos P, Quinn M, Desnick RJ. Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc Natl Acad Sci USA 1986; 83: 4859-63. (Pubitemid 16075498)
18. Mach L. Biosynthesis of lysosomal proeinases in health and disease. Biol Chem 2002; 383: 751-6. (Pubitemid 34649893)
19. Ghosh P, Dahms NM, Kornfeld S. Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol 2003; 4: 202-12. (Pubitemid 36288042)
20. Brady RO. Enzyme replacement for lysosomal disease. Annu Rev Med 2006; 57: 283-96.
21. De Graba T, Azhar S, Dignat-George F, Brown E. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 2000; 47: 229-33. (Pubitemid 30078570)
22. Kampmann C, Baehner F, Ries M, Beck M. Cardiac involvement in Anderson-Fabry disease. J Am Soc Nephrol 2002; 13(Supl. 2): S147-S149. (Pubitemid 34579227)
23. Kolodny EH, Pastores GM. Anderson-Fabry disease: extrarenal, neurologic manifestations. J Am Soc Nephrol 2002; 13(Supl. 2): S150-S153. (Pubitemid 34579228)
24. Das AM, Naim HY. Biochemical basis of Fabry disease with emphasis on mitochondiral funcition and protein trafficking. Adv Clin Chem 2009; 49: 57-71.
25. Pastores GM, Lien YH. Biochemical and molecular genetic basis of Fabry disease. J Am Soc Nephrol 2002; 13(Suppl. 2): 130-3.
26. Schafer E, Baron K, Widmer U, Deegan P, Neumann HP, Sounder-Plassmann G. Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease. Hum Mutat 2005; 25: 412-8.
27. Whybra C, Kampann C, Willers I, et al. Anderson-Fabry Disease: Clinical manifestation of disease in female heterozygotes. J Inherit Metab Dis 2001; 24: 715-24. (Pubitemid 34023880)
28. Vera-Sempere FJ, García A, Sánchez MA, et al. Nefropatía de células espumosas en mujer heterocigoto portadora de la enfermedad de Fabry. Nefrología 2002; 22: 287-92.
29. Desnik RJ, Brady R, Barraguer J, et al. Fabry disease, an under-recognized miltisystemic diseorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Inter Med 2003; 138: 338-46.
30. Torra R, Ballarin J. La enfermedad de Fabry. Nefrologia 2003; 23(Supl. 1): 84-9.
31. Clarke J. Narrative Review: Fabry Disease. Ann Intern Med 2007; 146: 425-33.
32. Eng CM, Fletcher J, Wilcox WR, et al. Fabry disease: baseline medical characteristic of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007; 30: 184-92. (Pubitemid 46487999)
33. Ramaswami U, Whybra C, Parini R, et al. Clinical manifestations of Fabry disease in children: data from Fabry Outcome Survey. Act Paediatr 2006; 95: 86-92. (Pubitemid 43041735)
34. Colombi A, Kostyal A, Bracher R, Gloor F, Mazzi R, Thölen H. Angiokeratoma corporis diffusum: Fabry's disease. Helv Med Act 1967; 34: 67-83.
35. McDermot KD, Hokmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38: 750-60. (Pubitemid 33032930)
36. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, et al. Natural History of Fabry renal disease: influence of alfa-galactosidase A activity and genetic mutations on clinical course. Medicine 2002; 81: 122-38. (Pubitemid 34218568)
37. Van Loo A, Vanholder R, Madsen K, Praet M, Kint J, De Paepe A, et al. Novel frameshift mutation in a heterozygous woman with Fabry disease and end-stage renal failure. Am J Nephrol 1996; 16: 352-7. (Pubitemid 26143588)
38. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestation and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38: 769-75. (Pubitemid 33032933)
39. Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG, et al. An atypical variant of Fabry's disease with manfestations confined to the myocardium. N Engl J Med 1991; 324: 395-9.
40. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995; 333: 288-93.
41. Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, Mc Kenna WJ, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002; 105: 1407-11. (Pubitemid 34263268)
42. Elleder M, Bradova V, Smid F, Budesinsky M, Harzer D, Kustermann-Kuhn, et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Virchows Arch A Pathol Anat Histopathol 1990; 417: 449-55. (Pubitemid 20345820)
43. O'Mahony C, Elliott P. Anderson-fabry disease and the heart. Prog Cardiovasc Dis 2010; 52(4): 326-35.
44. Meroni M, Sessa A, Battini G, et al. Kidney involvement in Anderson-Fabry disease. Contrib Nephrol 1997; 7: 179-84.
45. Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol 2002; 13(Suppl. 2): 134-8.
46. Hoffmann B. Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis 2009; 4: 21.
47. Lee K, Jin X, Zhang, Copertino L, Andrews IM, Baker-Malcolm J. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycopipid storage disorder Fabry disease. Glycobiology 2003; 13: 305-13. (Pubitemid 36592316)
48. Sakuraba H, Murata-Ohsawa M, Kawashima I, Tajima Y, Kotani M, Ohshima T. Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblast and Fabry mice. J Hum Genet 2006; 51: 180-8.
49. Banikazemi M, Bultas J, Waldek S. Fabry Disease Clinical Trial Study Group. Agalsidase-beta therapy for advanced Fabry disease: a randomiazed trial. Ann Intern Med 2007; 146(2): 77-86. (Pubitemid 351640010)
50. Vedder AC, Breuning F, Donker-Koopman WE, et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab 2008; 94(3): 319-25.
51. Thurberg BL, Byers HR, Grnater SR, et al. Monitoring the 3-year efficacy of enzyne replacement therapy in Fabry disease by repeated skin biopsies. J Invest Dermatol 2004; 122(4): 900-8. (Pubitemid 38580992)
52. Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme replacement therapy ob the cardiomyopathy of Anderson-Fabry disease; a randomised, double-blind, palcebo-controlled clinical trial of agalsidase alfa. Heart 2008; 94 (2): 153-8. (Pubitemid 351211719)
53. Metha A. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 2009; 374(4): 1986-96.
54. Ohashi T, Sakuma M, Kitagawa T, et al. Influence of antibody formation on reduction of globotriaosylceramide in urine from Fabry patients during agalsidase beta therapy. Mol Genet Metab 2007; 92(3): 271-3. (Pubitemid 47513559)
55. Hollark CE, Donker-Koopman WE. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Inter 2004; 66 (4): 1589-95. (Pubitemid 39298394)
56. Mengel E, Baron K, Kalkum G. Is there a neutralizing effect of antibodies against agalsidase alpha and beta? Act Paediatr 2007; 96(S455): 108.
57. Schafer R, Tylky-Szymanska, Hilz M. Enzyme replacement therapy for Fabry disease. A systemic review of available evidence. Drugs 2009; 69(16): 2179-205.
58. Sirrs S, Clarke JTR, Casey R, Lemoine K, Flowerdew G, Sinasa DS, West ML. Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative. Molecular Genetics and Metabolism 2010; 99: 367-73.
59. Sirrs S. Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative. Mol Genet Metab 2010; 99(4): 367-73.